PDMA's report, published in Japanese in March and translated into English in April, outlines the need for action. The agency notes "growing concerns about the expansion of drug loss n Japan, where pharmaceuticals approved in the EU and the US are not being developed for Japanese patients." The problem is particularly challenging for pediatric and orphan drugs, PMDA said.The post PMDA Outlines Initiatives to Promote Pediatric Drug Development in Japan appeared first on Global Regulatory Partners, Inc..
GRP is a Massachusetts-based company that provides services such as medical writing, health authority consultation, and product registration for the healthcare sector.